5 天之前 · AB Science to launch new Phase 3 trial of masitinib for ALS. AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update.

3 天之前 · Evaluating masitinib in ALS. A previous Phase 2/3 clinical trial (NCT02588677) tested two daily doses of masitinib (3 or 4.5 mg/kg) against a placebo in nearly 400 adults with ALS. The treatment was administered as an add-on to the approved ALS therapy Rilutek (riluzole) for nearly a year, or 48 weeks.. The study mainly sought to evaluate changes in disease progression, as assessed by the ALS ...

2024年12月30日 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found to slow ALS disease progression and lower levels of disease-related biomarkers in a small Phase 1 clinical trial. COYA 302 is a combination of an immune signaling molecule called interleukin-2 and a fusion protein called CTLA4-Ig ...

2025年1月27日 · Results from the studies showed that NP001 did not significantly slow disease progression relative to the placebo, as assessed by the ALS Functional Rating Scale Revised (ALSFRS-R). However, additional analyses indicated the treatment could slow disease progression and preserve lung function in a subset of middle-aged …

AB Science to launch new Phase 3 trial of masitinib for ALS. AB Science will launch a new Phase 3 clinical trial to test its investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS) whose disease is progressing normally and who haven’t completely lost physical function, according to a company update.

2024年1月2日 · No. 9 – Further questions set back European approval of AMX0035. Amylyx Pharmaceuticals’ application seeking the approval of AMX0035 in treating ALS patients across Europe faced a second round of questions from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The committee still had major objections to AMX0035 that needed to be addressed ...

4 天之前 · Ncyte Microglia contains microglia derived from induced pluripotent stem cells (iPSCs). These are created from skin or blood cells of healthy donors or patients and are reprogrammed into lab-made stem cells that can differentiate into almost any human cell type. iPSCs are then given specific chemical or biological cues that allow them to differentiate into microglia.

2025年1月8日 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the Centers for Disease Control and Prevention (CDC).

2022年12月30日 · No. 6 – “AMX0035 Extended Patients’ Survival By More Than 10 Months” The U.S. and Canada approvals of AMX0035 were supported by data from the Phase 2 CENTAUR clinical trial (NCT03127514).After six months in the initial placebo-controlled study, participants had the option to enroll in an open-label extension study (NCT03488524), where all were treated with the then-investigational therapy.

ALS News Today is a digital platform intended to provide the amyotrophic lateral sclerosis (ALS) community with the most recent news and information on ALS, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on ALS News Today are original content produced by in-house writers and editors. Occasionally, we seek the opinion of outside experts for ...